News in Brief: Benefits of early selexipag in PAH; Spike in empyema following introduction of 13-valent pneumococcal vaccine

Earlier the better for PAH treatment, RCT shows The benefits of initiating selexipag early in PAH has been further strengthened in the latest review of the GRIPHON trial – the largest RCT on PAH to date. The new post hoc analyses looked at the effect of time from diagnosis to initiation of selexipag based on ...

Already a member?

Login to keep reading.

© 2021 the limbic